Nexopamil racemate is the racemate of Nexopamil. Nexopamil is a combined Ca2+/5-HT2 antagonist on thrombus formation in vivo and on platelet aggregation in vitro.
Serotonin-induced platelet aggregation in dog platelet-rich plasma (PRP) in vitro is most potently inhibited by Nexopamil (IC50 81 nM) [1].
Nexopamil (0.05 mg/kg) completely abolishes cyclic flow reductions (CFRs) during the first 30 min after application without significantly altering hemodynamics[1].
[1]. Kirchengast M, et al. Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.